Amneal Pharmaceuticals, Inc. Amortization of Intangible Assets in USD from 2016 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
Summary
Amneal Pharmaceuticals, Inc. quarterly/annual Amortization of Intangible Assets history and growth rate from 2016 to Q3 2025.
  • Amneal Pharmaceuticals, Inc. Amortization of Intangible Assets for the quarter ending September 30, 2025 was $39.6M, a 8.55% decline year-over-year.
  • Amneal Pharmaceuticals, Inc. Amortization of Intangible Assets for the twelve months ending September 30, 2025 was $181M, a 10.3% increase year-over-year.
  • Amneal Pharmaceuticals, Inc. annual Amortization of Intangible Assets for 2024 was $174M, a 6.37% increase from 2023.
  • Amneal Pharmaceuticals, Inc. annual Amortization of Intangible Assets for 2023 was $163M, a 5.17% decline from 2022.
  • Amneal Pharmaceuticals, Inc. annual Amortization of Intangible Assets for 2022 was $172M, a 0.35% decline from 2021.
Amortization of Intangible Assets, Trailing 12 Months (USD)
Amortization of Intangible Assets, Quarterly (USD)
Amortization of Intangible Assets, YoY Quarterly Growth (%)
Amortization of Intangible Assets, Annual (USD)
Amortization of Intangible Assets, YoY Annual Growth (%)

Amneal Pharmaceuticals, Inc. Quarterly Amortization of Intangible Assets (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $181M $39.6M -$3.7M -8.55% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-06
Q2 2025 $185M $45.8M +$5.7M +14.2% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-07
Q1 2025 $179M $45.2M +$5.3M +13.3% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-07
Q4 2024 $174M $50.3M +$9.6M +23.6% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-28
Q3 2024 $164M $43.3M +$2.7M +6.65% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-06
Q2 2024 $161M $40.1M -$700K -1.72% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-07
Q1 2024 $162M $39.9M -$1.2M -2.92% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-07
Q4 2023 $163M $40.7M -$4M -8.95% Oct 1, 2023 Dec 31, 2023 10-K 2025-02-28
Q3 2023 $167M $40.6M -$3.9M -8.76% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 $171M $40.8M -$1.2M -2.86% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-09
Q1 2023 $172M $41.1M +$200K +0.49% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $172M $44.7M +$1M +2.29% Oct 1, 2022 Dec 31, 2022 10-K 2025-02-28
Q3 2022 $171M $44.5M +$691K +1.58% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $170M $42M -$1.52M -3.49% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $172M $40.9M -$772K -1.85% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $173M $43.7M -$168K -0.38% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-14
Q3 2021 $173M $43.8M -$739K -1.66% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 $174M $43.5M -$456K -1.04% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 $174M $41.7M -$904K -2.12% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-06
Q4 2020 $175M $43.9M +$3.69M +9.18% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-03
Q3 2020 $171M $44.5M +$6.53M +17.2% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 $165M $44M +$9.18M +26.4% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 $156M $42.6M +$11.6M +37.5% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-07
Q4 2019 $144M $40.2M -$59.7M -59.8% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-01
Q3 2019 $204M $38M +$12.4M +48.2% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-06
Q2 2019 $191M $34.8M +$18.1M +108% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 $173M $31M +$29.2M +1659% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 $144M $99.8M Oct 1, 2018 Dec 31, 2018 10-K 2021-03-01
Q3 2018 $25.7M +$24.4M +1907% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 $16.7M +$15.8M +1784% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-05
Q1 2018 $1.76M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q3 2017 $1.28M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-07
Q2 2017 $886K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09

Amneal Pharmaceuticals, Inc. Annual Amortization of Intangible Assets (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $174M +$10.4M +6.37% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-28
2023 $163M -$8.9M -5.17% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-28
2022 $172M -$600K -0.35% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-28
2021 $173M -$2.27M -1.3% Jan 1, 2021 Dec 31, 2021 10-K 2024-03-14
2020 $175M +$31M +21.5% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-03
2019 $144M $0 0% Jan 1, 2019 Dec 31, 2019 10-K 2022-03-01
2018 $144M +$71M +97.2% Jan 1, 2018 Dec 31, 2018 10-K 2021-03-01
2017 $73M +$69.3M +1872% Jan 1, 2017 Dec 31, 2017 10-K 2021-03-01
2016 $3.7M Jan 1, 2016 Dec 31, 2016 10-K 2019-03-01
* An asterisk sign (*) next to the value indicates that the value is likely invalid.